Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial

Abstract

Importance: It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock.

Objective: To determine whether the combination of vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, improves the duration of time alive and free of vasopressor administration in patients with septic shock.

Design, setting, and participants: Multicenter, open-label, randomized clinical trial conducted in 10 intensive care units in Australia, New Zealand, and Brazil that recruited 216 patients fulfilling the Sepsis-3 definition of septic shock. The first patient was enrolled on May 8, 2018, and the last on July 9, 2019. The final date of follow-up was October 6, 2019.

Interventions: Patients were randomized to the intervention group (n = 109), consisting of intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours), or to the control group (n = 107), consisting of intravenous hydrocortisone (50 mg every 6 hours) alone until shock resolution or up to 10 days.

Main outcomes and measures: The primary trial outcome was duration of time alive and free of vasopressor administration up to day 7. Ten secondary outcomes were prespecified, including 90-day mortality.

Results: Among 216 patients who were randomized, 211 provided consent and completed the primary outcome measurement (mean age, 61.7 years [SD, 15.0]; 133 men [63%]). Time alive and vasopressor free up to day 7 was 122.1 hours (interquartile range [IQR], 76.3-145.4 hours) in the intervention group and 124.6 hours (IQR, 82.1-147.0 hours) in the control group; the median of all paired differences was -0.6 hours (95% CI, -8.3 to 7.2 hours; P = .83). Of 10 prespecified secondary outcomes, 9 showed no statistically significant difference. Ninety-day mortality was 30/105 (28.6%) in the intervention group and 25/102 (24.5%) in the control group (hazard ratio, 1.18; 95% CI, 0.69-2.00). No serious adverse events were reported.

Conclusions and relevance: In patients with septic shock, treatment with intravenous vitamin C, hydrocortisone, and thiamine, compared with intravenous hydrocortisone alone, did not significantly improve the duration of time alive and free of vasopressor administration over 7 days. The finding suggests that treatment with intravenous vitamin C, hydrocortisone, and thiamine does not lead to a more rapid resolution of septic shock compared with intravenous hydrocortisone alone.

Trial registration: ClinicalTrials.gov Identifier: NCT03333278.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Shehabi reported receipt of grants, personal fees, and nonfinancial support from Orion Pharma and Pfizer and grants from the National Health and Medical Research Council of Australia. Dr Hajjar reported receiving grants from the Hospital Sírio Libanês. Dr Udy reported receiving in-kind support from Integra LifeSciences (trial consumables) for work unrelated to this study. No other disclosures were reported.

Figures

Figure 1.. Flow of Participants in the Vitamin C, Hydrocortisone, and Thiamine in Patients With Septic Shock (VITAMINS) Trial

aMultiple reasons for exclusion were possible.

Figure 2.. Kaplan-Meier Analysis by Randomization Group

Proportionality assumptions were met (P = .33 for interaction of the randomization group with logarithm of time). Overall incidence of death was not significantly different between the groups (log-rank P = .55).

Figure 3.. Vasopressor Use During the First 10 Days of the Trial

Use of vasopressors was defined as any use of norepinephrine, epinephrine, vasopressin, metaraminol, dopamine, or phenylephrine. Data on doses of vasopressors were obtained every 6 hours, and the 4 doses per day were summed for the vasopressor dose on that study day. Total vasopressor doses was calculated as the sum of norepinephrine doses and converted doses of epinephrine and vasopressin. Patients receiving metaraminol monotherapy did not contribute to total vasopressor dose data, and no patients received dopamine or phenylephrine. Box center lines are medians, box tops and bottoms are interquartile ranges, and error bars are ranges. The trajectory curves connect the daily medians.